UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 12b-25

NOTIFICATION OF LATE FILING
 
1-16817
Commission File Number
 
(Check one):
 
x Form 10-K
o Form 20-F
o Form 11-K
o Form 10-Q
o Form 10-D
   
o Form N-SAR
o Form N-CSR
     
             
   
For Period Ended:
December 31, 2014
   
o Transition Report on Form 10-K
   
   
o Transition Report on Form 20-F
   
   
o Transition Report on Form 11-K
   
   
o Transition Report on Form 10-Q
   
   
o Transition Report on Form N-SAR
   
   
For the Transition Period Ended:
 
 
Read Instructions (on back page) Before Preparing Form. Please Print or Type.
Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.
 
If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:
 

 
PART I — REGISTRANT INFORMATION
 
New York Global Innovations Inc.
Full Name of Registrant
 
InkSure Technologies, Inc.
Former Name if Applicable
 
18 East 16th Street, Suite 307
Address of Principal Executive Office (Street and Number)
 
New York, NY 10003
City, State and Zip Code
 
PART II — RULES 12b-25(b) AND (c)
 
If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)
 
 
(a)
The reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense
x
(b)
The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-SAR or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and
 
(c)
The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.
 
 
 

 
 
PART III — NARRATIVE

State below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-SAR, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.
 
New York Global Innovations Inc., or the Company, is unable to timely file its Annual Report on Form 10-K for the year ended December 31, 2014, or the 2014 Annual Report.  As a result of the time required for the Company’s auditor to complete its review of the Company’s consolidated financial statements, the Company has experienced an unanticipated delay in completing its consolidated financial statements and required disclosures necessary for the filing of the 2014 Annual Report.
 
The Company currently expects to file the 2014 Annual Report within the 15 calendar day extension period provided by Rule 12b-25.
 
PART IV — OTHER INFORMATION
 
(1)
Name and telephone number of person to contact in regard to this notification
 
 
Gadi Peleg
 
212
 
697-1463
 
(Name)
 
(Area Code)
 
(Telephone Number)
   
(2)
Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s).
 
x Yes    o No
       
(3)
Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?
 
x Yes    o No
           
 
If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.
   
 
As a result of substantially all of the Company’s assets being sold in February 2014, the Company no longer has revenue-producing operations and, accordingly, the results to be reported for 2014 will differ significantly from those reported for 2013.
 
 
 

 

New York Global Innovations Inc.

(Name of Registrant as Specified in Charter)
 
has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.
 
Date
March 31, 2015
 
By
/s/ Chanan Morris
       
Chanan Morris
       
(Principal Financial and Accounting Officer, and Chief Financial Officer)
 
INSTRUCTION: The form may be signed by an executive officer of the registrant or by any other duly authorized representative. The name and title of the person signing the form shall be typed or printed beneath the signature. If the statement is signed on behalf of the registrant by an authorized representative (other than an executive officer), evidence of the representative’s authority to sign on behalf of the registrant shall be filed with the form.
 
 
ATTENTION
 
Intentional misstatements or omissions of fact constitute Federal Criminal Violations (See 18 U.S.C. 1001).



Artemis Therapeutics (PK) (USOTC:ATMS)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Artemis Therapeutics (PK) Charts.
Artemis Therapeutics (PK) (USOTC:ATMS)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Artemis Therapeutics (PK) Charts.